With a $1.8 billion purchase with CinCor, AstraZeneca grows its heart and kidney businesses.
9 January (Reuters) AstraZeneca (AZN.L) declared on Monday that it has reached an agreement to acquire American drug-development company CinCor Pharma Inc (CINC.O) for up to $1.8 billion in order to expand its supply of heart and kidney medications.
The experimental medication baxdrostat, which is being developed by CinCor to treat illnesses like high blood pressure and chronic renal disease, is at the heart of the agreement.
